Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - vardenafil hydrochloride 23,7 mg - eq. vardenafil 20 mg - film-coated tablet - 20 mg - vardenafil hydrochloride 23.7 mg - vardenafil

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - vardenafil hydrochloride 11,85 mg - eq. vardenafil 10 mg - film-coated tablet - 10 mg - vardenafil hydrochloride 11.85 mg - vardenafil

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vardenafil hydrochloride 5,926 mg - eq. vardenafil 5 mg - film-coated tablet - 5 mg - vardenafil hydrochloride 5.926 mg - vardenafil

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vardenafil hydrochloride 11,853 mg - eq. vardenafil 10 mg - film-coated tablet - 10 mg - vardenafil hydrochloride 11.853 mg - vardenafil

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - vardenafil hydrochloride 23,705 mg - eq. vardenafil 20 mg - film-coated tablet - 20 mg - vardenafil hydrochloride 23.705 mg - vardenafil

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - vardenafil hydrochloride trihydrate - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - vardenafil hydrochloride trihydrate - oral tablet - 10mg

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil is not indicated for use in females. there are no data with the use of vardenafil in pregnant women to inform any drug-associated risks. in animal reproduction studies conducted in pregnant rats and rabbits, no adverse deve

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - vardenafil hydrochloride trihydrate (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil for the safe administration of nitrates or nitric oxide donors has not been determined.  do not use vardenafil in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil may potentiate the hypotensive effects of gc stimulators. pregnancy category b vardenafil is not indicated for use in women. there are no studies of vardenafil use in pregnant women. no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil hydrochloride may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil hydrochloride for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil hydrochloride is not indicated for use in females. there are no data with the use of vardenafil hydrochloride in pregnant women to inform any drug-associat